Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Operating Expenses: 2022-2025

Historic Operating Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $53.7 million.

  • Stoke Therapeutics' Operating Expenses rose 53.95% to $53.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.4 million, marking a year-over-year increase of 33.12%. This contributed to the annual value of $137.9 million for FY2024, which is 11.63% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Operating Expenses of $53.7 million as of Q3 2025, which was up 30.66% from $41.1 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Operating Expenses peaked at $53.7 million during Q3 2025, and registered a low of $27.8 million during Q1 2022.
  • Moreover, its 3-year median value for Operating Expenses was $34.2 million (2024), whereas its average is $36.7 million.
  • Data for Stoke Therapeutics' Operating Expenses shows a peak YoY spiked of 53.95% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Operating Expenses stood at $30.4 million in 2022, then increased by 6.39% to $32.4 million in 2023, then rose by 11.98% to $36.3 million in 2024, then spiked by 53.95% to $53.7 million in 2025.
  • Its Operating Expenses stands at $53.7 million for Q3 2025, versus $41.1 million for Q2 2025 and $47.3 million for Q1 2025.